— Vertex Pharmaceuticals (NASDAQ: VRTX) reported third-quarter 2019 earnings of $1.23 per share, vs. $1.15 per share expected
— Total revenue grew 21% to $949.8 million, vs $950.9 million expected.
— Reiterated FY19 product revenues guidance of $3.70 – 3.75 billion. Non-GAAP effective tax rate outlook was also unchanged at 21-22%.
— VRTX shares were down 0.14% immediately following the announcement.
Production disruption and logistics issues continue to have a crippling effect on the industrial sector but the performance of companies, in general, has been mixed so far. Fastenal Company (NASDAQ:
Netflix, Inc. (NASDAQ: NFLX) Thursday said it added 8.3 million paid members in the December quarter. Revenues increased and matched estimates, aided by the relaxation of COVID restrictions and resumption
Investment management firm Charles Schwab Corporation (NYSE: SCHW) has stayed largely unaffected by the coronavirus crisis, rather it managed to tap into new opportunities. The company owes its impressive financial